| Name | Title | Contact Details |
|---|---|---|
David Berman |
Chief Financial Officer | Profile |
As a company, we believe in digital health for everyone everywhere. We have created a new category of therapeutic product – the digital health feedback system – to allow people of all ages and cultures to power their own health, taking better care of themselves and each other. We see two trends: First, there are more people with mobile phones than there are with access to clean, running water. Second, chronic, often lifestyle-related diseases like diabetes are the world’s biggest healthcare problem, and our health systems can’t cope because they are optimized to treat the acute conditions prevalent decades ago. Our vision is to integrate medicines that treat chronic conditions with mobile technology – via our ingestible sensor – to make healthcare more accessible, manageable and innovative. We believe that by providing the right technology to individuals who deliver and receive healthcare, we can build a more effective healthcare system with new care paradigms focused on daily care and new information-based business models.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.
OrthoFX have the best materials technology in the industry, due in large part to Loc Phan, the key scientist behind developing the first ever clear aligner. We are committed to continued polymer technology innovation by hiring a team of industry experts like Loc to understand your needs and pain points, and we can`t do it without your partnership.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Oxyheal Health Group is a National City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.